Shares of ValiRx plc (LON:VAL – Get Free Report) hit a new 52-week low during trading on Wednesday . The company traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.39 ($0.04), with a volume of 56258 shares trading hands. The stock had previously closed at GBX 3.30 ($0.04).
ValiRx Stock Up 2.7 %
The business’s 50-day moving average is GBX 3.73 and its two-hundred day moving average is GBX 6.42. The firm has a market capitalization of £4.48 million, a price-to-earnings ratio of -112.93 and a beta of 0.63. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.27 and a current ratio of 13.37.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than ValiRx
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- AMD is Down 35%. Now is the Time to Buy the Dip
- 3 Warren Buffett Stocks to Buy Now
- Amazon Stands Tall: New Highs Are in Sight
- How Investors Can Find the Best Cheap Dividend Stocks
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
